IN2005KO00272A - - Google Patents
Download PDFInfo
- Publication number
- IN2005KO00272A IN2005KO00272A IN272KO2005A IN2005KO00272A IN 2005KO00272 A IN2005KO00272 A IN 2005KO00272A IN 272KO2005 A IN272KO2005 A IN 272KO2005A IN 2005KO00272 A IN2005KO00272 A IN 2005KO00272A
- Authority
- IN
- India
- Prior art keywords
- carbon atoms
- halogen
- alkyl
- formula
- alkenyl
- Prior art date
Links
- 125000004432 carbon atom Chemical group C* 0.000 abstract 24
- 125000003342 alkenyl group Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical group 0.000 abstract 6
- 125000004950 trifluoroalkyl group Chemical group 0.000 abstract 5
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 101100134925 Gallus gallus COR6 gene Proteins 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pregnancy & Childbirth (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
Abstract
A process for the preparation of a compound of formula I, having the structure wherein R1 is alkenyl of 2-7 carbon atoms; wherein the alkenyl moiety is optionally substituted with hydroxyl, -CN, halogen, trifluoroalkyl of 1-6 carbon atoms, trifluoroalkoxy of 1-6 carbon atoms, -COR5, -CO2R5, -NO2, CONR5R6, NR5R6 or N(R5)COR6; R2 and R2a are each, independently, hydrogen, hydroxyl, halogen, alkyl of 1-6 carbon atoms, alkoxy of 1-4 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, trifluoroalkyl of 1-6 carbon atoms, or trifluoroalkoxy of 1-6 carbon atoms; wherein the alkyl, alkenyl, or alkynyl moieties are optionally substituted with hydroxyl, -CN, halogen, trifluoroalkyl of 1-6 carbon atoms, trifluoroalkoxy of 1-6 carbon atoms, -COR5, -CO2R5, -NO2, CONR5R6, NR5R6 or N(R5)COR6; R3, and R3a are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, halogen, alkoxy of 1-4 carbon atoms, trifluoroalkyl of 1-6 carbon atoms, or trifluoroalkoxy of 1-6 carbon atoms; wherein the alkyl, alkenyl, or alkynyl moieties are optionally substituted with hydroxyl, -CN, halogen, trifluoroalkyl of 1-6 carbon atoms, trifluoroalkoxy of 1-6 carbon atoms, -COR5, -CO2R5, -NO2, CONRsRe, NR5R6 or N(R5)COR6; R5, R6 are each, independently hydrogen, alkyl of 1-6 carbon atoms or aryl of 6-10 carbon atoms; X is O, S, or NR7; R7 is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-10 carbon atoms, -COR5, -CO2R5 or -SO2R5; or a pharmaceutically acceptable salt thereof; comprising one of the following a) reacting a compound of formula wherein R1, R2, R2a. and X are as defined above with a compound of formula wherein R3 and R3a are as defined above and Y is halogen, -OH or hydroxyalkyl of 1 to 6 carbon atoms; or b) converting a compound of formula I as defined above to a pharmaceutically acceptable salt thereof; or c) resolving an Isomeric mixture of compounds of formula I as defined above to isolate an enantiomer of a compound of formula I or a pharmaceutically acceptable salt thereof,
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33666301P | 2001-12-05 | 2001-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2005KO00272A true IN2005KO00272A (en) | 2015-08-07 |
Family
ID=23317104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN272KO2005 IN2005KO00272A (en) | 2001-12-05 | 2005-04-04 |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US6794403B2 (en) |
| EP (2) | EP1982713A3 (en) |
| JP (2) | JP4689960B2 (en) |
| KR (1) | KR20050044717A (en) |
| CN (2) | CN100443477C (en) |
| AR (1) | AR037745A1 (en) |
| AU (2) | AU2002353014A1 (en) |
| BR (1) | BR0214767A (en) |
| CA (1) | CA2467517C (en) |
| CO (1) | CO5580830A2 (en) |
| EC (1) | ECSP045133A (en) |
| HU (1) | HUP0500010A2 (en) |
| IL (1) | IL162256A0 (en) |
| IN (1) | IN2005KO00272A (en) |
| MX (1) | MXPA04005306A (en) |
| NO (1) | NO20042811L (en) |
| NZ (1) | NZ560878A (en) |
| PL (1) | PL370771A1 (en) |
| RU (2) | RU2330847C2 (en) |
| SG (1) | SG165987A1 (en) |
| TW (1) | TW200304822A (en) |
| UA (1) | UA83620C2 (en) |
| WO (1) | WO2003050095A1 (en) |
| ZA (1) | ZA200405249B (en) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1448544E (en) | 2001-11-19 | 2007-08-10 | Lilly Co Eli | Substituted benzopyrans as selective estrogen receptor-beta agonists |
| UA83620C2 (en) | 2001-12-05 | 2008-08-11 | Уайт | Substituted benzoxazoles and analogues as estrogenic agents |
| US20040002524A1 (en) * | 2002-06-24 | 2004-01-01 | Richard Chesworth | Benzimidazole compounds and their use as estrogen agonists/antagonists |
| TW200409759A (en) * | 2002-09-25 | 2004-06-16 | Wyeth Corp | Substituted 4-(indazol-3-yl)phenols |
| DK1587821T6 (en) | 2002-12-19 | 2025-05-26 | Scripps Research Inst | Compositions and methods for stabilizing trans-thyretin and inhibiting transthyretin misfolding |
| DE602004016150D1 (en) * | 2003-04-21 | 2008-10-09 | Lilly Co Eli | SUBSTITUTED BENZOPYRANES AS SELECTIVE ANTAGONISTS ON THE OSTROGEN RECEPTOR BETA |
| TW200500065A (en) * | 2003-05-21 | 2005-01-01 | Wyeth Corp | Antiarthritic combinations |
| AU2005245470A1 (en) * | 2004-05-20 | 2005-12-01 | Foldrx Pharmaceuticals, Inc. | 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| EP1761513A1 (en) * | 2004-07-01 | 2007-03-14 | Wyeth | Tetracyclic compounds as estrogen ligands |
| KR20070046148A (en) * | 2004-08-26 | 2007-05-02 | 와이어쓰 | Prodrug-substituted benzoxazoles as estrogen agonists |
| RU2007108713A (en) | 2004-09-02 | 2008-10-10 | Вайет (Us) | Phenanthridinecarbonylphenols as cytokine modulators |
| US7354927B2 (en) | 2004-09-07 | 2008-04-08 | Wyeth | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents |
| CA2588454A1 (en) * | 2004-12-02 | 2006-06-08 | Wyeth | Formulations of substituted benzoxazoles |
| CA2589103A1 (en) * | 2004-12-02 | 2006-06-08 | Wyeth | Formulations of substituted benzoxazoles |
| WO2006060532A2 (en) * | 2004-12-02 | 2006-06-08 | Wyeth | Formulations of substituted benzoxazoles |
| BRPI0519111A2 (en) * | 2004-12-17 | 2008-12-23 | Wyeth Corp | methods for treating parkinson's disease, improving a symptom of parkinson's disease and improving a symptom of a cognitive disease or disorder, and use of a selective erbeta ligand |
| WO2006088716A1 (en) * | 2005-02-15 | 2006-08-24 | Eli Lilly And Company | Substituted tetralins as selective estrogen receptor-beta agonists |
| BRPI0608154A2 (en) * | 2005-02-16 | 2016-10-11 | Wyeth Corp | methods of treating or inhibiting mucositis, radiation cystitis in an individual, and treating at least one symptom of an individual's exposure to a cytotoxic agent or radiation, and, pharmaceutical composition |
| CA2601973A1 (en) * | 2005-03-07 | 2006-09-14 | Wyeth | Process for the preparation of substituted benzoxazole compounds |
| MX2007010895A (en) * | 2005-03-07 | 2007-12-05 | Wyeth Corp | Process for the purification of substituted benzoxazole compounds. |
| US7683182B2 (en) * | 2005-03-08 | 2010-03-23 | Wyeth Llc | Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| BRPI0610308A8 (en) | 2005-05-26 | 2017-04-25 | Neuron Systems Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RETINAL DISEASE |
| TW200804345A (en) | 2005-08-30 | 2008-01-16 | Novartis Ag | Substituted benzimidazoles and methods of preparation |
| BRPI0707655A2 (en) * | 2006-02-14 | 2011-05-10 | Wyeth Corp | aqueous pharmaceutical composition, method for preparing a pharmaceutical composition, product, method for treating an individual suffering from arthritis or endometriosis, and kit |
| PE20080117A1 (en) * | 2006-03-06 | 2008-02-22 | Wyeth Corp | PHARMACEUTICAL FORMULATIONS OF AN ANHYDROUS CRYSTALLINE FORM OF 2- (3-FLUOR-4-HYDROXYPHENIL) -7-VINYL-1,3-BENZOXAZOLE-5-OL |
| WO2007103877A2 (en) * | 2006-03-06 | 2007-09-13 | Wyeth | Pharmaceutical formulations of a monohydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| MX2008011459A (en) * | 2006-03-06 | 2008-09-24 | Wyeth Corp | Tablet formulations and processes. |
| US20070207201A1 (en) * | 2006-03-06 | 2007-09-06 | Wyeth | Liquid and Semi-Solid Pharmaceutical Formulations and Processes |
| JP4986485B2 (en) | 2006-03-28 | 2012-07-25 | 株式会社Ａｄｅｋａ | Epoxy resin curable composition |
| WO2008034016A2 (en) * | 2006-09-15 | 2008-03-20 | Foldrx Pharmaceuticals, Inc. | Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins |
| US20080132554A1 (en) * | 2006-11-21 | 2008-06-05 | Wyeth | Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20080176914A1 (en) * | 2006-11-21 | 2008-07-24 | Wyeth | Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20080175901A1 (en) * | 2006-11-21 | 2008-07-24 | Wyeth | Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20090239920A1 (en) * | 2006-11-21 | 2009-09-24 | Wyeth | Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20080146630A1 (en) * | 2006-11-21 | 2008-06-19 | Wyeth | Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20080175900A1 (en) * | 2006-11-21 | 2008-07-24 | Wyeth | Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20080241234A1 (en) * | 2006-11-21 | 2008-10-02 | Wyeth | Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| WO2008064217A2 (en) * | 2006-11-21 | 2008-05-29 | Wyeth | Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol and pharmaceutical formulations thereof |
| US20080139633A1 (en) * | 2006-11-21 | 2008-06-12 | Wyeth | Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US9623021B2 (en) * | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| US9078888B2 (en) | 2007-01-22 | 2015-07-14 | Gtx, Inc. | Nuclear receptor binding agents |
| US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
| MX2009008121A (en) * | 2007-01-31 | 2009-08-12 | Wyeth Corp | Use of erî² selective ligands for treating acute lung injuries. |
| WO2008100769A2 (en) * | 2007-02-09 | 2008-08-21 | Wyeth | Process for selective sulfation of aromatic hydroxyl groups |
| US20080262009A1 (en) * | 2007-04-20 | 2008-10-23 | Wyeth | Crystalline polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as acetate salts |
| US20080262010A1 (en) * | 2007-04-20 | 2008-10-23 | Wyeth | Crystalline polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as d-glucoronate salts |
| US20080275073A1 (en) * | 2007-04-20 | 2008-11-06 | Wyeth | Crystalline forms and polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as pharmaceutically acceptable salts |
| US20080262008A1 (en) * | 2007-04-20 | 2008-10-23 | Wyeth | Crystalline forms and polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as succinate salts |
| WO2009009417A2 (en) * | 2007-07-06 | 2009-01-15 | Wyeth | Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion |
| JP2011511803A (en) * | 2008-02-08 | 2011-04-14 | ワイス・エルエルシー | Phosphate derivatives of substituted benzoxazoles |
| WO2010036908A1 (en) * | 2008-09-26 | 2010-04-01 | Eisai R & D Management Co., Ltd. | Use of benzoxazole compounds in the treatment of malaria |
| EP2350032B1 (en) | 2008-09-26 | 2016-05-25 | Eisai R&D Management Co., Ltd. | Benzoxazole compounds and methods of use |
| WO2010083199A1 (en) | 2009-01-19 | 2010-07-22 | Abbott Laboratories | Benzthiazole inhibitors of poly(adp-ribose)polymerase |
| WO2011014516A1 (en) | 2009-07-28 | 2011-02-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Estrogen antagonists as treatments for sclerosing disorders |
| WO2011072141A1 (en) | 2009-12-11 | 2011-06-16 | Neuron Systems, Inc. | Compositions and methods for the treatment of macular degeneration |
| AU2011308775B2 (en) * | 2010-10-01 | 2016-11-17 | Indiana University Research And Technology Corporation | Treatment of symptoms associated with menopause |
| WO2012118935A1 (en) * | 2011-03-03 | 2012-09-07 | Proteotech Inc | Compounds for the treatment of neurodegenerative diseases |
| CN103781770B (en) | 2011-09-16 | 2016-04-13 | 辉瑞公司 | Transthyretin dissociates the solid form of inhibitor |
| AU2013366867B2 (en) * | 2012-12-27 | 2017-06-01 | Sumitomo Chemical Company, Limited | Fused oxazole compounds and use thereof for pest control |
| EP2948149A4 (en) | 2013-01-23 | 2016-12-14 | Aldeyra Therapeutics Inc | DISEASES RELATED TO TOXIC ALDEHYDE AND TREATMENT |
| SG11201505599YA (en) | 2013-01-25 | 2015-08-28 | Aldeyra Therapeutics Inc | Novel traps in the treatment of macular degeneration |
| EP3178810A4 (en) * | 2014-08-08 | 2018-07-04 | Kasuma Partners Inc. | Condensed heterocyclic compound |
| WO2016036721A1 (en) | 2014-09-02 | 2016-03-10 | The Regents Of The University Of California | Estrogen receptor ligand treatment for neurodegenerative diseases |
| CN104926745A (en) * | 2015-07-14 | 2015-09-23 | 佛山市赛维斯医药科技有限公司 | Compounds containing benzisoxazole and terminal halogenation benzyl structures and application thereof |
| CN104974103A (en) * | 2015-07-14 | 2015-10-14 | 佛山市赛维斯医药科技有限公司 | Compound containing benzisoxazole and alcoxylphenyl structure and application thereof |
| MX2018002155A (en) | 2015-08-21 | 2018-06-08 | Aldeyra Therapeutics Inc | DEUTERATED COMPOUNDS AND USES OF THE SAME. |
| MX2018013472A (en) | 2016-05-09 | 2019-02-28 | Aldeyra Therapeutics Inc | TREATMENT OF COMBINATION OF OCULAR INFLAMMATORY DISORDERS AND DISEASES. |
| CN110431130A (en) | 2017-03-16 | 2019-11-08 | 奥尔德拉医疗公司 | Polymorphic compounds and their uses |
| AU2018348174A1 (en) | 2017-10-10 | 2020-04-23 | Aldeyra Therapeutics, Inc. | Treatment of inflammatory disorders |
| CN108586374B (en) * | 2018-01-12 | 2021-01-05 | 浙江鼎龙科技有限公司 | Preparation method of 2-phenylbenzoxazole compound |
| EP3833660A4 (en) | 2018-08-06 | 2022-05-11 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| WO2020223717A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| JP2022530967A (en) | 2019-05-02 | 2022-07-05 | アルデイラ セラピューティクス， インコーポレイテッド | Polymorphic compounds and their use |
| CN111467341B (en) * | 2020-04-24 | 2021-05-11 | 山东师范大学 | Application of 3,4-dimethoxyphenyl-benzo[d]oxazole as a tumor resistance reversal agent |
| WO2021231792A1 (en) | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| CN114805112A (en) * | 2022-05-31 | 2022-07-29 | 常州大学 | PDE2 inhibitor amide derivative and preparation method thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1435721A (en) * | 1972-05-18 | 1976-05-12 | Lilly Industries Ltd | Benzoxazole derivatives |
| GB1590587A (en) | 1977-06-28 | 1981-06-03 | Lilly Industries Ltd | Benoxaprofen |
| EP0694535A1 (en) * | 1994-04-29 | 1996-01-31 | Eli Lilly And Company | Non-peptidyl tachykinin receptor antagonists |
| EP0935000A3 (en) | 1995-09-08 | 1999-09-08 | Karo Bio Ab | Orphan receptor |
| WO1998017267A1 (en) | 1996-10-23 | 1998-04-30 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
| US5948776A (en) * | 1996-10-23 | 1999-09-07 | Zymogenetic, Inc. | Compositions and methods for treating bone deficit conditions |
| US5919808A (en) * | 1996-10-23 | 1999-07-06 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
| US7157568B1 (en) | 1997-08-05 | 2007-01-02 | American Home Products Corporation | Human estrogen receptor-β |
| WO1999057115A1 (en) | 1998-05-05 | 1999-11-11 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Novel benzimidazoles and benzoxazoles |
| SI1095040T1 (en) | 1998-07-06 | 2004-10-31 | Altana Pharma Ag | New benzoxazoles with pde-inhibiting activity |
| GB9814620D0 (en) | 1998-07-06 | 1998-09-02 | Karobio Ab | Vasculoprotector |
| AU1199600A (en) | 1998-10-02 | 2000-04-26 | Board Of Trustees Of The University Of Illinois, The | Estrogen receptor ligands |
| WO2000031112A1 (en) | 1998-11-20 | 2000-06-02 | Akzo Nobel N.V. | Estrogenic estra-1,3,5(10)-trienes with differential effects on the alpha and beta estrogen receptors, having a linear hydrocarbon chain of from 5-9 carbon atoms in position 11 |
| JP2002533456A (en) | 1998-12-30 | 2002-10-08 | シグナル ファーマシューティカルズ， インコーポレイテッド | Compounds and methods for modulating estrogen receptors |
| US6331562B1 (en) * | 1998-12-30 | 2001-12-18 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| US6358943B1 (en) * | 1999-03-04 | 2002-03-19 | American Home Products Corporation | N-substituted indolines as estrogenic agents |
| AU766648B2 (en) * | 1999-03-17 | 2003-10-23 | Axys Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| WO2000059897A2 (en) | 1999-04-06 | 2000-10-12 | Akzo Nobel N.V. | Esters and carbonates of 2-(4-hydroxyphenyl)-6(or 5)-hydroxy-benzothiophene derivatives as selective estrogenic compounds |
| WO2000061230A2 (en) | 1999-04-09 | 2000-10-19 | Karo Bio Ab | Estrogen receptors-beta antagonism and bone diseases |
| EE200100526A (en) | 1999-04-16 | 2002-12-16 | Astrazeneca Ab | Estrogen β-receptor ligands |
| US6159959A (en) * | 1999-05-06 | 2000-12-12 | American Home Products Corporation | Combined estrogen and antiestrogen therapy |
| GB9913649D0 (en) | 1999-06-11 | 1999-08-11 | Karobio Ab | Estrogen receptor |
| US6380166B1 (en) * | 1999-09-13 | 2002-04-30 | American Home Products Corporation | Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols |
| US7087599B2 (en) | 2000-02-14 | 2006-08-08 | Merck & Co., Inc. | Estrogen receptor modulators |
| WO2002046168A1 (en) * | 2000-12-07 | 2002-06-13 | Astrazeneca Ab | Therapeutic benzimidazole compounds |
| JP2004524289A (en) * | 2000-12-22 | 2004-08-12 | アストラゼネカ・アクチエボラーグ | Therapeutic compounds |
| US6559177B2 (en) * | 2001-04-19 | 2003-05-06 | Wyeth | 5, 11-Dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents |
| UA83620C2 (en) | 2001-12-05 | 2008-08-11 | Уайт | Substituted benzoxazoles and analogues as estrogenic agents |
| KR20070046148A (en) * | 2004-08-26 | 2007-05-02 | 와이어쓰 | Prodrug-substituted benzoxazoles as estrogen agonists |
-
2002
- 2002-03-12 UA UA20040705301A patent/UA83620C2/en unknown
- 2002-12-03 SG SG200603829-3A patent/SG165987A1/en unknown
- 2002-12-03 NZ NZ560878A patent/NZ560878A/en unknown
- 2002-12-03 RU RU2004120283/04A patent/RU2330847C2/en active
- 2002-12-03 KR KR1020047008680A patent/KR20050044717A/en not_active Abandoned
- 2002-12-03 AU AU2002353014A patent/AU2002353014A1/en not_active Abandoned
- 2002-12-03 JP JP2003551120A patent/JP4689960B2/en not_active Expired - Fee Related
- 2002-12-03 MX MXPA04005306A patent/MXPA04005306A/en active IP Right Grant
- 2002-12-03 WO PCT/US2002/038513 patent/WO2003050095A1/en not_active Ceased
- 2002-12-03 PL PL02370771A patent/PL370771A1/en unknown
- 2002-12-03 EP EP07023848A patent/EP1982713A3/en not_active Withdrawn
- 2002-12-03 CN CNB028278186A patent/CN100443477C/en not_active Expired - Fee Related
- 2002-12-03 TW TW091135030A patent/TW200304822A/en unknown
- 2002-12-03 HU HU0500010A patent/HUP0500010A2/en unknown
- 2002-12-03 EP EP02789980A patent/EP1451165A1/en not_active Withdrawn
- 2002-12-03 CN CNA2008101731403A patent/CN101423500A/en active Pending
- 2002-12-03 IL IL16225602A patent/IL162256A0/en unknown
- 2002-12-03 BR BR0214767-0A patent/BR0214767A/en not_active IP Right Cessation
- 2002-12-03 CA CA2467517A patent/CA2467517C/en not_active Expired - Fee Related
- 2002-12-04 AR ARP020104690A patent/AR037745A1/en unknown
- 2002-12-04 US US10/309,699 patent/US6794403B2/en not_active Expired - Fee Related
-
2004
- 2004-05-17 US US10/847,100 patent/US7148247B2/en not_active Expired - Fee Related
- 2004-06-01 CO CO04050963A patent/CO5580830A2/en not_active Application Discontinuation
- 2004-06-04 EC EC2004005133A patent/ECSP045133A/en unknown
- 2004-07-01 ZA ZA200405249A patent/ZA200405249B/en unknown
- 2004-07-02 NO NO20042811A patent/NO20042811L/en not_active Application Discontinuation
- 2004-08-19 US US10/921,409 patent/US7129258B2/en not_active Expired - Fee Related
-
2005
- 2005-04-04 IN IN272KO2005 patent/IN2005KO00272A/en unknown
-
2006
- 2006-12-11 US US11/636,947 patent/US7531564B2/en not_active Expired - Fee Related
-
2008
- 2008-02-26 RU RU2008107295/04A patent/RU2008107295A/en not_active Application Discontinuation
-
2009
- 2009-08-17 AU AU2009210357A patent/AU2009210357A1/en not_active Ceased
-
2010
- 2010-11-15 JP JP2010255175A patent/JP2011052010A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2005KO00272A (en) | ||
| PT915866E (en) | APPROPRIATE PROCESS FOR THE SYNTHESIS OF PROTEED ESTERS OF (S) -3,4-DIHYDROXYBUTYRIC ACID | |
| PT96897A (en) | METHOD FOR PREPARING NEW ARIL-AND HETEROARILETILENIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| BG103980A (en) | 4-phenylpiperidine compounds | |
| NZ504372A (en) | Process to produce N-[3-fluoro-4(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinones | |
| MX23884A (en) | XANTINA DERIVATIVES AND PROCEDURE FOR ITS PREPARATION. | |
| NZ505220A (en) | Arylpiperazines having activity at the serotonin 1A receptor, processes for their preparation and intermediates | |
| PT1064281E (en) | BENZO-HETEROCYCLIC DISTAMICINE DERIVATIVES PROCESS FOR THE PREPARATION AND THEIR USE AS ANTITUMATIC AGENTS | |
| CO4990933A1 (en) | INDAZOL TRICYCLIC DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | |
| HUP9900680A2 (en) | Acyclic nucleoside derivatives, process for producing them, pharmaceutical compositions containing them and method for the treatment of viral infections | |
| MY118004A (en) | Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents | |
| MY127317A (en) | Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain | |
| PT1303514E (en) | PROCESS FOR THE PREPARATION OF AZACICLOALCANOYLAMINOTIAZOLES | |
| PL1628968T3 (en) | 4-imidazolin-2-one compounds | |
| HUP9900679A2 (en) | Benzimidazole derivatives as inhibitors of smooth muscle cell proliferation, process for producing them and pharmaceutical compositions containing them | |
| PT982305E (en) | The present invention relates to a process for the preparation of the compounds of the general formulas (I) and (II) to the pharmaceutically acceptable excipients. | |
| CY1107481T1 (en) | ANTIOELECTIVE alkylation of tricyclic compounds | |
| HUP9902040A2 (en) | Process for producing 4-phenyl-1,2,3,6-tetrahydro-pyridine derivatives and the intermediates employed | |
| GB9812211D0 (en) | Cinnamoyl distamycin analogous derivatives,process for their preparation,and their use as antitumor agents | |
| ATE337300T1 (en) | HYDROXYLATED INDIRUBINE DERIVATIVES | |
| ATE238300T1 (en) | (3,4-DIHYDRO-2H-BENZO(1,4)OXAZINYL-METHYL)-3-(1 - INDOL-3-YL)-ALKYLAMINES | |
| DOP2001000226A (en) | PROCESS FOR PREPARING 2- (4-PIRIDIL) AMINO-6-DIALQUI- LOXIFENIL-PIRIDO [2,3-D] PIRIMIDIN-7-ONAS (PROCESS FOR PREPARING 2- (4-PYRIDIL) AMINO-6-DIALKYPHENYL-PYRIDO 2 , 3-D] | |
| ES8604591A1 (en) | PROCEDURE FOR PREPARING NEW 11-PIPERAZINYL-5H-IMIDAZO (2,1-C) (1,4) -BENZODIAZEPINES | |
| NZ506912A (en) | Fungicidal 6-(2-halo-4-alkoxyphenyl)- triazolopyrimidines | |
| HUP0301798A2 (en) | Treatment of eating disorders using carboxyalkylethers |